NovoCure secured Japan approval ahead of results for NovoCure stock

Published on 10/18/2026 at 12:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NovoCure secured Japan approval for Optune Pax on October 1, 2026. October 29 results will test NovoCure stock after Q2 revenue reached USD 183.58 million.

Three dated signals for investors

Japan approved Optune Pax for pancreatic cancer treatment on October 1, 2026.
Second-quarter revenue reached USD 183.58 million, up 15.60 percent year over year.
NovoCure will report third-quarter 2026 results on October 29, 2026.

NVCR, JE00BYSS4X48, Illustration mit AI erstellt.

NovoCure Limited (JE00BYSS4X48) secured Japanese approval for Optune Pax on October 1, 2026, expanding the oncology company's regulatory footprint in pancreatic cancer. The approval arrived ahead of the company's scheduled third-quarter results, giving investors two dated milestones to assess. Novocure said the Japanese health ministry approved Optune Pax for adults with unresectable, locally advanced pancreatic cancer alongside chemotherapy.

Japan expands Optune Pax reach

The decision was based on the Phase 3 PANOVA-3 trial, which met its primary endpoint by showing a statistically significant improvement in median overall survival. The release also reported device-related skin adverse events in 76.30 percent of treated participants, while 7.70 percent experienced a Grade 3 or higher event.

For NovoCure, the approval adds a commercial opportunity to an already expanding product portfolio. Optune Pax received U.S. approval in February 2026 and a CE Mark in June 2026, according to the October 1 company release.

What does revenue mean for margins?

NovoCure's second-quarter 2026 revenue reached USD 183.58 million, 15.60 percent above the prior-year quarter. MarketBeat reported that the adjusted loss was USD 0.13 per share versus a USD 0.33 consensus loss. The comparison shows stronger revenue execution alongside continuing losses.

Market data dated October 16, 2026, put NovoCure's market capitalization at USD 1.6 billion and its 52-week range at USD 9.82 to USD 21.45. The company therefore enters the October reporting date with growth in the latest reported quarter but a profitability question still visible in the numbers.

October 29 sets the next date

Novocure will report third-quarter 2026 results on October 29, 2026, before the U.S. financial markets open, with its conference call scheduled for 8:00 a.m. EDT. That report will show whether the revenue trajectory and regulatory expansion are translating into further progress toward profitability.

Nasdaq listing and oncology focus

The company's ordinary shares trade on the Nasdaq Stock Market under ticker NVCR, as identified in its October 1, 2026 filing with the SEC. NovoCure develops Tumor Treating Fields, a non-invasive therapy platform for aggressive cancers. The Japanese approval and the upcoming results date make product adoption and operating losses the two measurable issues for the next update.

Investor context

On October 16, 2026, NovoCure's market capitalization was USD 1.6 billion, while the latest reported quarter delivered USD 183.58 million in revenue. NovoCure's next scheduled financial event is October 29, 2026, before the U.S. market open. The further course of trading is shown by the continuously updated real-time quote of NovoCure stock.